Medicus Pharma plans SkinJect combination with undisclosed SPAC
MDCX•Medicus Pharma’s SkinJect unit signed a nonbinding letter of intent to combine with an undisclosed SPAC in a deal valuing SkinJect at $135 million pre-money. Completion is anticipated in the first half of 2027, subject to definitive agreements, financing and other closing conditions.
1. Proposed combination
Medicus Pharma’s SkinJect unit signed a nonbinding letter of intent to combine with an undisclosed special purpose acquisition company. The proposed deal values SkinJect at $135 million pre-money enterprise value, with 100% of the unit to be acquired in exchange for newly issued common shares.
2. Funding and timeline
SkinJect would become a separately listed company, while Medicus Pharma seeks to retain majority economic and voting ownership. Concurrent equity financing would support the SKNJCT-005 Gorlin syndrome study and preparation and submission of a potential New Drug Application. Completion is anticipated in the first half of 2027, subject to definitive agreements, financing and other closing conditions.
